SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference
SeaStar Medical (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, announced its participation in the HC Wainwright 27th Annual Global Investment Conference.
The company's presentation is scheduled for September 5, 2025, at 7:00 am ET. Investors can access the presentation through the Events & Presentations page in the Investor Relations section of SeaStar Medical's website, where it will remain available for 60 days after the event.
SeaStar Medical (Nasdaq: ICU), azienda sanitaria in fase commerciale specializzata nei trattamenti per pazienti critici con insufficienza d'organo, ha annunciato la propria partecipazione alla HC Wainwright 27th Annual Global Investment Conference.
La presentazione è in programma per il 5 settembre 2025 alle 7:00 ET. Gli investitori potranno visualizzarla nella pagina Events & Presentations, nella sezione Investor Relations del sito di SeaStar Medical; sarà disponibile per 60 giorni dopo l'evento.
SeaStar Medical (Nasdaq: ICU), una compañía sanitaria en fase comercial especializada en tratamientos para pacientes críticos con fallo orgánico, anunció su participación en la HC Wainwright 27th Annual Global Investment Conference.
La presentación está programada para el 5 de septiembre de 2025 a las 7:00 ET. Los inversores podrán acceder a la presentación en la página Events & Presentations de la sección Investor Relations del sitio web de SeaStar Medical; permanecerá disponible durante 60 días después del evento.
SeaStar Medical (Nasdaq: ICU)는 장기부전으로 위중한 환자 치료를 전문으로 하는 상업 단계의 의료 기업으로, HC Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다.
회사는 2025년 9월 5일 오전 7:00 ET에 프레젠테이션을 진행할 예정입니다. 투자자들은 SeaStar Medical 웹사이트의 Investor Relations 섹션 내 Events & Presentations 페이지에서 자료에 접속할 수 있으며, 이벤트 후 60일 동안 이용할 수 있습니다.
SeaStar Medical (Nasdaq: ICU), entreprise en phase commerciale spécialisée dans les traitements des patients en état critique atteints d'insuffisance organique, a annoncé sa participation à la HC Wainwright 27th Annual Global Investment Conference.
La présentation est prévue le 5 septembre 2025 à 7h00 ET. Les investisseurs pourront consulter la présentation sur la page Events & Presentations de la section Investor Relations du site de SeaStar Medical ; elle restera disponible pendant 60 jours après l'événement.
SeaStar Medical (Nasdaq: ICU), ein Unternehmen in der kommerziellen Phase, das sich auf Behandlungen für kritisch kranke Patienten mit Organversagen spezialisiert hat, gab seine Teilnahme an der HC Wainwright 27th Annual Global Investment Conference bekannt.
Die Präsentation ist für den 5. September 2025 um 7:00 Uhr ET angesetzt. Investoren können die Präsentation auf der Seite Events & Presentations im Investor-Relations-Bereich der SeaStar Medical-Website abrufen; sie wird nach der Veranstaltung für 60 Tage verfügbar bleiben.
- None.
- None.
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference.
The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website, and will be available for 60 days following the presentation.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. It was approved in 2024 by the U.S. Food and Drug Administration (FDA). QUELIMMUNE is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the US annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
IR@SEASTARMED.COM
FAQ
When is SeaStar Medical (ICU) presenting at the HC Wainwright Conference?
How can investors access SeaStar Medical's HC Wainwright Conference presentation?
How long will SeaStar Medical's HC Wainwright presentation be available online?
What is SeaStar Medical's (ICU) business focus?
